CD8-β CRISPR/Cas9 KO Plasmid (h): sc-400950
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD8-β CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CD8-β genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD8-β Antibody (F-5): sc-25277
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD8-β CRISPR/Cas9 KO Plasmid (h) | sc-400950 | 20 µg | $397.00 |
Overview
CD8B encodes CD8-β, a type I transmembrane glycoprotein that heterodimerizes with CD8-α to form the CD8 co-receptor on cytotoxic T lymphocytes and subsets of thymocytes. By binding MHC class I and associating with LCK, CD8-β enhances TCR signaling strength, supporting antigen-specific activation, immunological synapse formation, and downstream pathways controlling proliferation, cytokine production, and cytolytic effector differentiation. CD8B expression contributes to thymic selection and maintenance of CD8+ T-cell identity, influencing immune surveillance and responses to infection. Dysregulated CD8 co-receptor signaling and altered CD8B expression patterns are relevant to studies of autoimmunity, chronic inflammation, tumor immunology, and T-cell exhaustion phenotypes.
CD8-β CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CD8B gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CD8B together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CD8B open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CD8-β protein expression.
This CRISPR knockout system enables efficient generation of CD8B-deficient cell models for investigation of CD8-β signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CD8B exon(s) critical for CD8-β function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CD8B genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CD8-β CRISPR/Cas9 KO Plasmid (h) and CD8-β CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CD8B locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CD8-β HDR Plasmid (h) and CD8-β HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CD8B homology arms to support homology-directed repair at defined CD8B target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.